These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 23030290)

  • 1. Genetic influences of angiotensin-converting enzyme inhibitor response: an opportunity for personalizing therapy?
    Brugts JJ; Simoons ML
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):1001-9. PubMed ID: 23030290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy.
    Brugts JJ; Danser AH; de Maat MP; den Uil CA; Boersma E; Ferrari R; Simoons ML
    Curr Opin Cardiol; 2008 Jul; 23(4):296-301. PubMed ID: 18520711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of antihypertensive treatment.
    Arnett DK; Claas SA; Glasser SP
    Vascul Pharmacol; 2006 Feb; 44(2):107-18. PubMed ID: 16356784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The renin-angiotensin-aldosterone system: approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease.
    Brugts JJ; den Uil CA; Danser AH; Boersma E
    Cardiology; 2009; 112(4):303-12. PubMed ID: 18832826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibitors in hypertension: a review.
    Salvetti A; Pedrinelli R; Arzilli F; Abdel-Haq B; Magagna A; Lucarini A; Graziadei L; Nuccorini A; Taddei S
    Int J Clin Pharmacol Res; 1985; 5(6):429-38. PubMed ID: 3005182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit.
    Brugts JJ; Boersma E; Simoons ML
    Pharmacogenomics; 2010 Aug; 11(8):1115-26. PubMed ID: 20712529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.
    Brugts JJ; de Maat MP; Boersma E; Witteman JC; van Duijn C; Uitterlinden AG; Bertrand M; Remme W; Fox K; Ferrari R; Danser AH; Simoons ML;
    Cardiovasc Drugs Ther; 2009 Apr; 23(2):171-81. PubMed ID: 19082699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
    Krum H; Gilbert RE
    J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects.
    Katragadda S; Arora RR
    Am J Ther; 2010; 17(1):e11-23. PubMed ID: 20090429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetes.
    Bozkurt O; de Boer A; Grobbee DE; Kroon AA; Schiffers P; de Leeuw P; Klungel OH
    J Renin Angiotensin Aldosterone Syst; 2009 Jun; 10(2):101-8. PubMed ID: 19502258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor.
    Costa-Scharplatz M; van Asselt AD; Bachmann LM; Kessels AG; Severens JL
    Pharmacogenet Genomics; 2007 May; 17(5):359-68. PubMed ID: 17429318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril.
    He H; Li LM; Cao WH; Sun NL; Liu MZ; Hu YH
    Ann Hum Biol; 2005; 32(1):30-43. PubMed ID: 15788353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [ACE gene polymorphism as a risk factor in the development of hypertensive organ damage].
    Yamasaki E; Nakura J
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():104-7. PubMed ID: 15171350
    [No Abstract]   [Full Text] [Related]  

  • 16. Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure.
    Wu CK; Luo JL; Tsai CT; Huang YT; Cheng CL; Lee JK; Lin LY; Lin JW; Hwang JJ; Chiang FT
    Pharmacogenomics J; 2010 Feb; 10(1):46-53. PubMed ID: 19752885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of pneumonia risk by an angiotensin I-converting enzyme inhibitor in elderly Japanese inpatients according to insertion/deletion polymorphism of the angiotensin I-converting enzyme gene.
    Takahashi T; Morimoto S; Okaishi K; Kanda T; Nakahashi T; Okuro M; Murai H; Nishimura Y; Iwai K; Matsumoto M
    Am J Hypertens; 2005 Oct; 18(10):1353-9. PubMed ID: 16202861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New aspects of the renin-angiotensin system: angiotensin-converting enzyme 2 - a potential target for treatment of hypertension and diabetic nephropathy.
    Batlle D; Soler MJ; Wysocki J
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):250-7. PubMed ID: 18408475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the renin-angiotensin-aldosterone system and cough.
    Lacourcière Y; Lefebvre J
    Can J Cardiol; 1995 Aug; 11 Suppl F():33F-39F. PubMed ID: 7664216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.